Check Point Care scales hospital‑at‑home push after MEDICA 2025 with EIC support
- ›EIC Accelerator awardee Check Point Care used EIC International Trade Fairs support at MEDICA 2025 to generate hospital interest and distributor leads
- ›Company reports meetings with medical device makers and pilot commitments from university hospitals in Germany, Sweden and the UK, with an initial home monitoring roll out of about 1,000 patients
- ›Check Point Care says it has over 10,000 pending orders for its next generation wearable portfolio while pursuing MDR certification and an EUR 8.5 million Series A
- ›The solution combines continuous medical grade physiological livestreaming, an AI platform producing thousands of digital biomarkers and a virtual ward for remote clinical oversight
- ›Scaling will depend on clinical validation, regulatory clearance, reimbursement and integration with hospital IT and procurement cycles
How MEDICA 2025 and EIC support accelerated hospital pilots for Check Point Care
Check Point Care, a Bulgarian healthtech company and EIC Accelerator awardee, says participation at MEDICA 2025 under the European Innovation Council International Trade Fairs Programme materially advanced its commercialisation. With EIC matchmaking and pavilion exposure, the company reports prearranged meetings with large medical device groups, interest from hospital networks, distributor enquiries and more than 10,000 pending orders for its next generation wearable monitoring devices.
What the technology claims to do
The company describes three core technology pillars. First, wearable hardware that continuously streams more than 19 vital parameters. Second, an AI platform that extracts large sets of derived signals and digital biomarkers to construct a digital twin for each patient and detect deterioration patterns. Third, a virtual ward interface for clinicians to track trends, communicate with care teams and intervene remotely. Check Point Care says the next generation wearable family includes a lightweight bracelet connected to a chest device to enable monitoring across acute and chronic populations.
What MEDICA 2025 delivered and how EIC helped
Check Point Care credits the EIC Pavilion and the International Trade Fairs Programme with tangible access to senior decision makers, higher visitor traffic than a standalone booth and speaking slots for company leadership. The company reports meetings with major medical device companies to explore integration opportunities, interest from at least 10 qualified distributors and pilot discussions with leading university hospitals in Germany, Sweden and the United Kingdom. In Italy the company says engagement continued with a major private hospital chain and a regional public hospital already running studies.
| Metric | Reported figure | Comment |
| Pending device orders | More than 10,000 | Company statement. Pending status means orders not yet fulfilled or revenue recognised |
| Initial pilot patients | Approximately 1,000 | Planned across university hospitals in Germany, Sweden and the UK |
| Distributors expressing interest | At least 10 | Across multiple markets |
| MDR certification | Expected in September | Medical Device Regulation compliance is required for broader EU market access |
| Planned Series A | EUR 8.5 million | To support commercial expansion and AI development |
Regulatory, clinical and commercial realities to watch
The narrative given by the company and the EIC emphasises rapid commercial traction. That is plausible given strong interest in remote monitoring as healthcare systems seek hospital capacity relief. At the same time there are routine frictions between early market interest and durable uptake. These include regulatory clearance, rigorous clinical validation, procurement cycles, reimbursement and integration with hospital IT and clinical workflows.
Funding, EIC support and next steps
Check Point Care has progressed its product development under an EIC funded project named ArchAngel which the company says strengthened its R and D. It is now aiming to close a Series A round of €8.5 million to scale commercial activities and further develop its AI capabilities. The company also plans to continue leveraging EIC Business Acceleration Services for coaching, visibility through the EIC Scaling Club and ecosystem partnerships including EIC ACCESS+.
Why the story matters for European healthtech
Check Point Care illustrates how EIC promotional and matchmaking activities can convert trade fair exposure into meetings and potential pilots. The example underlines two broader dynamics in European healthtech. First, demand for hospital‑at‑home and continuous monitoring solutions is real and driven by system capacity pressures. Second, moving from interest to deployment depends on a sequence of regulatory approvals, clinical validation, procurement and reimbursement. EIC support can lower early access barriers but it cannot substitute for the evidence and integration work hospitals require before scaling new digital clinical services.
For investors and procurement teams the company’s stated 10,000 pending orders is a headline number that merits careful scrutiny. Pending orders can reflect reservation lists, expressions of interest or distributor preorders that are contingent on certification, delivery timelines and contractual terms. The path to converting interest into realised revenue and patient benefit remains long and operationally demanding.
Practical implications and monitoring checkpoints
| Checkpoint | What to watch for | Why it matters |
| MDR certification | Proof of compliance and device class determination | Needed for EU market access and contracting with hospitals |
| Pilot outcomes | Clinical performance, alert accuracy, false alarm rates, workflow impact | Determines clinical adoption and value case for procurement |
| Reimbursement pathway | National or regional tariffs, procurement frameworks, inclusion in tenders | Without reimbursement business model may rely on hospital budgets or private pay |
| Integration | EHR connectivity, standards use, IT security audits | Affects deployment speed and clinician acceptance |
| Order conversion | Contract signatures, delivery schedules, recognition of revenue | Benchmarks real commercial traction beyond expressions of interest |
| Series A close | Funding receipts and use of proceeds | Determines commercial runway and ability to scale internationally |
Check Point Care is now prioritising the United Kingdom and Germany followed by Scandinavia and the Benelux for expansion. That market sequencing reflects where hospital interest, procurement opportunities and willingness to pilot remote monitoring are often strongest in Europe. If the company converts pilots into evidence and secures regulatory clearance, it could capture a meaningful niche in hospital‑at‑home services. If it does not, the company will face the familiar gap between promising early engagement and mainstream adoption.
Bottom line
The Check Point Care case is a concrete example of how EIC trade fair programmes can accelerate introductions and create market momentum for European healthtech. It also exposes the typical hurdles ahead. Success will depend on timely regulatory clearance, credible clinical evidence, robust IT integration, procurement and reimbursement outcomes and the company’s ability to convert reported interest into binding contracts and deliveries. Observers and potential partners should treat early headline figures as indicators to be validated against subsequent regulatory milestones and pilot results.